Filing Details
- Accession Number:
- 0001127602-20-010505
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-03-12 18:56:29
- Reporting Period:
- 2020-03-11
- Accepted Time:
- 2020-03-12 18:56:29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875045 | Biogen Inc. | BIIB | Biological Products, (No Disgnostic Substances) (2836) | 330112644 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1079462 | A Stephen Sherwin | Biogen Inc. 225 Binney Street Cambridge MA 02142 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-03-11 | 10,923 | $58.46 | 16,517 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-03-11 | 2,164 | $295.22 | 14,353 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-03-11 | 1,355 | $58.46 | 15,708 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-03-11 | 270 | $295.29 | 15,438 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-03-11 | 10,923 | $0.00 | 10,923 | $59.82 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-03-11 | 1,355 | $0.00 | 1,355 | $59.82 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2020-03-22 | No | 4 | M | Direct | |
| 0 | 2011-03-22 | 2020-03-22 | No | 4 | M | Direct |
Footnotes
- Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
- This option was previously reported as covering 10,675 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017.
- This option was previously reported as covering 1,325 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017.
- Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC Rule 16(b)-3(d).
- The stock options become exercisable in three (3) equal annual installments commencing one year after the grant date of 03/22/2010.
Billionaire Hedge Funds
